Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys-Reference-Cited by-同舟云学术

Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys

Published:2016 Issue: Volume:5 Page:e319
ISSN:2162-2531
Container-title:Molecular Therapy - Nucleic Acids
language:en
Short-container-title:Molecular Therapy - Nucleic Acids

Author:

Shemesh Colby S,Yu Rosie Z,Gaus Hans J,Greenlee Sarah,Post Noah,Schmidt Karsten,Migawa Michael T,Seth Punit P,Zanardi Thomas A,Prakash Thazha P,Swayze Eric E,Henry Scott P,Wang Yanfeng

Publisher

Elsevier BV

Subject

Drug Discovery,Molecular Medicine

Reference31 articles.

1. Molecular mechanisms of action of antisense drugs;Crooke;Biochim Biophys Acta,1999

2. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform;Bennett;Annu Rev Pharmacol Toxicol,2010

3. Delivery materials for siRNA therapeutics;Kanasty;Nat Mater,2013

4. Bioconjugates for targeted delivery of therapeutic oligonucleotides;Ming;Adv Drug Deliv Rev,2015

5. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice;Prakash;Nucleic Acids Res,2014

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolism of new drug modalities research advances – 2023 year in review;Drug Metabolism Reviews;2024-07-05

2. Metabolite profiling of chemically modified oligonucleotides in rat liver homogenates using hydrophilic interaction liquid chromatography-high resolution mass spectrometry;Microchemical Journal;2024-07

3. Drug–Drug Interactions of FXI Inhibitors: Clinical Relevance;Hematology Reports;2024-03-21

4. Safety and Tolerability of GalNAc₃-Conjugated Antisense Drugs Compared to the Same-Sequence 2′-O-Methoxyethyl-Modified Antisense Drugs: Results from an Integrated Assessment of Phase 1 Clinical Trial Data;Nucleic Acid Therapeutics;2024-02-01

5. Treatment of ATTR Amyloidosis: From Stabilizers to Gene Editing;Cardiac Amyloidosis;2024